Role of Genetic Factors in the Development of Lung Disease
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers. Optional CT Sub-study The standard CT scan will be compared to the low dose radiation CT scan for the 150 subjects enrolled in the sub-study to assess the variation between the two techniques. Specifically, the quantitative computer aided detection of lung CT abnormalities from LAM can be compared to assess whether low radiation dose CT exams is an alternative to conventional CT to monitor disease status. This optional sub-study will be offered to up to 100 adult subjects with lung disease and up to 50 children age 9 and older with CF. Children will not be enrolled in the optional CT sub-study unless they have had a standard CT scan for medical purposes to use in comparison. One additional low dose radiation CT scan of the chest may be done as part of this sub-study when these subjects have their next annual CT scan....
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza niedoboru AAT (zagrażająca forma)
- •Objawy choroby płuc (kaszel, duszność, problemy z oddychaniem)
- •Wyniki badań obrazowych (rentgen klatki piersiowej) wskazujące na chorobę płuc
- •Wyniki testów funkcji płuc potwierdzające chorobę
- •Osoby palące (minimum 1 paczka dziennie przez 2 lata) lub niepałące
- •Pacjenci z mukowiscydozą z potwierdzonym defektem genetycznym
- •Pacjenci z sarkoidozą, zapaleniem płuc, włóknieniem, astmą lub histiocytozą X
- •Dzieci z mukowiscydozą powyżej 8 lat oraz z limfangiomatozą powyżej 2 lat
Simplified criteria — AI translation
Trial details
- Minimum age
- 2 Years
- Maximum age
- 90 Years
- Last updated (source)
- July 17, 2026
- Sex
- No restrictions
Locations (2)
Suburban Hospital
Bethesda, United States
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
Tatyana A Worthy, R.N.
Joel Moss, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.